The Indiana Institute for Personalized Medicine explores how genetic information and environmental exposure affect each person's risk to develop certain diseases and response to medication.
The Institute examines how this new model of genome-informed personalized healthcare may be translated in clinical settings to advance the practice, delivery and economics of health care.
While personalized medicine is transforming the health system as we know it, we are bridging the gap between genomics research and patient care.
The Division of Clinical Pharmacology at the Indiana University School of Medicine seeks an outstanding scientist and clinician to join our world class team of scientists, clinicians and educators. The Division includes 24 primary and adjunct faculty with interests that span the breadth of the discipline. It is supported by University cores that include drug analysis, pharmacogenomics, computational biology, and simulation and modeling. The Division is also the site of important clinical pharmacology training programs that include stable and funded adult, pediatric, obstetric and modeling programs. The successful applicant will be an individual with an M.D. or M.D., Ph.D. degree and a record of scientific accomplishment in the form of peer-reviewed publications and funding. We seek an individual with a track record of excellent verbal, written communication and administrative skills. The successful candidate will establish a laboratory program, serve as a key leader in the Department of Medicine and be an integral part of a multidisciplinary team.
Send curriculum vitae and names of three references to: Attention: Dr. David Flockhart, Division of Clinical Pharmacology, Myers Building, WD W7123, 1001 W. 10th Street, Indianapolis, IN 46202. Women and underrepresented minorities are encouraged to apply. Indiana University is an EEO/AA Employer, M/F/D.
IIPM MEMBERS IN THE NEWS
Posted on July 25, 2013
Educational Conference on Personalized Medicine and Pharmacogenomics
"Pharmacogenomics in Clinical Practice…What you need to know"
Thursday, September 5, 2013 from 8:30am – 3:00pm
The Indiana Institute of Personalized Medicine is offering a didactic and case-study oriented educational conference focusing on pharmacogenomics and its application in clinical practice.The IIPM, led by Dr. Flockhart and a select group of clinicians and pharmacogenomic experts, will conduct a CME and ACPE qualified program addressing the use of pharmacogenomics in clinical practice. The program will be held at the IU Health Neuroscience Center Auditorium at 355 West 16th Street Indianapolis IN 46202. Read more...
Posted on March 6, 2012
AGS honors IU professor for outstanding achievement in geriatric care
In recognition of his significant contributions to the health care of older adults, Regenstrief Institute investigator Malaz Boustani, M.D., MPH, associate professor of medicine at the Indiana University School of Medicine, will receive the 2012 American Geriatrics Society Outstanding Scientific Achievement for Clinical Investigation Award. The honor will be presented at the American Geriatrics Society annual meeting in Seattle in May. Read more...
IIPM Associate Director Bryan Schneider, MD: 2012 Forty Under 40
Dr. Bryan Schneider is an associate professor of medicine at the Indiana University Melvin and Bren Simon Cancer Center. He holds appointments in the Divisions of Hematology/Oncology and Clinical Pharmacology in the Department of Medicine with a secondary appointment in the Department of Medical and Molecular Genetics.
He is a recipient of the prestigious Komen Promise Award and his achievements in breast cancer research have earned him a spot on this year's celebrated IBJ Forty Under 40 list.
Read his full story and watch the interview online at the Indianapolis Business Journal.
Cocktail of Popular Drugs May Cloud Brain
From The New York Time Health Blog
Many people are unaware that dozens of painkillers, antihistamines and psychiatric medications — from drugstore staples to popular antidepressants — can adversely affect brain function, mostly in the elderly. Regular use of multiple medications that have this effect has been linked to cognitive impairment and memory loss. Read more...
From Indianapolis Discovery Network for Dementia (IDND)
To assist with the recognition of these medications, Dr. Malaz A. Boustani and an interdisciplinary team developed the Anticholinergic Cognitive Burden (ACB) list as a practical tool that identifies the severity of anticholinergic effects on cognition of both prescription and over-the-counter medications. Read more...
IN OTHER NEWS
Posted on June 19, 2012
Indiana leads U.S. in life sciences jobs and growth
From the BioCrossroads news room
Indiana has moved up the life sciences ladder and is now at the top of the leading national list. According to a Battelle/Biotechnology Industry Organization (BIO) Report "State Bioscience Industry Development 2012" released today at the BIO International Conference in Boston, Indiana is one of only two states (along with Puerto Rico) that have specialized bioscience employment in four of the five subsectors - Agricultural Feedstock & Chemicals, Drugs & Pharmaceuticals, Medical Devices & Equipment, Research, Testing & Medical Laboratories, and a new subsector, Bioscience Distribution (which includes agricultural seeds, biomedical equipment and supplies, and drugs and pharmaceuticals). Read more...
Posted on August 22, 2011
Johns Hopkins Lands $30M for Personalized Cancer Center
From the GenomeWeb Daily News
The Johns Hopkins Kimmel Cancer Center will use a $30 million donation from the Commonwealth Foundation for Cancer Research to fund a new center that will focus on genomics and personalized cancer medicine research. Read more...
Posted on August 10, 2011
The Path to Personalized Medicine
From the The New England Journal of Medicine
Major investments in basic science have created an opportunity for significant progress in clinical medicine. Researchers have discovered hundreds of genes that harbor variations contributing to human illness, identified genetic variability in patients' responses to dozens of treatments, and begun to target the molecular causes of some diseases. In addition, scientists are developing and using diagnostic tests based on genetics or other molecular mechanisms to better predict patients' responses to targeted therapy. Read more...
- AGS honors IU professor for outstanding achievement in geriatric care